Hepatitis B

Infectious Disease·MeSH: Hepatitis B

Prevalence

900.0 / 100K

Incidence

10.0 / 100K/yr

71 drugs in development·21 companies·12 clinical trials

Drug Pipeline by Phase

Phase 2(31)
DrugCompany
ab-729Arbutus Biopharma Corp (ABUS)
ALG-000184Aligos Therapeutics, Inc. (ALGS)
ARC-520 InjectionARROWHEAD PHARMACEUTICALS, INC. (ARWR)
bepirovirsenIONIS PHARMACEUTICALS INC (IONS)
chadox1-hbvBarinthus Biotherapeutics plc. (BRNS)
chlorpheniramineARROWHEAD PHARMACEUTICALS, INC. (ARWR)
daplusiran/tomligisiranARROWHEAD PHARMACEUTICALS, INC. (ARWR)
entecavirARROWHEAD PHARMACEUTICALS, INC. (ARWR)
hepatitis b vaccinePOINT Biopharma Global Inc. (PNT)
imdusiranArbutus Biopharma Corp (ABUS)
imdusiran (AB-729)Arbutus Biopharma Corp (ABUS)
mva-hbvBarinthus Biotherapeutics plc. (BRNS)
nasPOINT Biopharma Global Inc. (PNT)
nucleoside analogsSPRING PHARMACEUTICAL GROUP, INC. (CYIG)
peg-ifnPOINT Biopharma Global Inc. (PNT)
peg-ifnαVir Biotechnology, Inc. (VIR)
Peg-IFNα-2aArbutus Biopharma Corp (ABUS)
pegylated interferon alpha 2aARROWHEAD PHARMACEUTICALS, INC. (ARWR)
pegylated interferon-alfa 2aVir Biotechnology, Inc. (VIR)
pevifoscorvirAligos Therapeutics, Inc. (ALGS)
rg6346Dicerna Pharmaceuticals Inc (DRNA)
selgantolimodGILEAD SCIENCES, INC. (GILD)
tdfAligos Therapeutics, Inc. (ALGS)
tenofovir alafenamideGILEAD SCIENCES, INC. (GILD)
tenofovir disoproxilARROWHEAD PHARMACEUTICALS, INC. (ARWR)
tqa3334SPRING PHARMACEUTICAL GROUP, INC. (CYIG)
vbi-2601VBI VACCINES INC/BC (VBIV)
vir-2218Vir Biotechnology, Inc. (VIR)
vir-2218GILEAD SCIENCES, INC. (GILD)
vir-3434Vir Biotechnology, Inc. (VIR)
VTP-300Barinthus Biotherapeutics plc. (BRNS)
Phase 1(26)
DrugCompany
AB-101Arbutus Biopharma Corp (ABUS)
abi-4334ASSEMBLY BIOSCIENCES, INC. (ASMB)
ABI-4334 (4334)ASSEMBLY BIOSCIENCES, INC. (ASMB)
acetaminophenARROWHEAD PHARMACEUTICALS, INC. (ARWR)
Acetaminophen 1000 mg/dARROWHEAD PHARMACEUTICALS, INC. (ARWR)
Acetaminophen 4000 mg/dARROWHEAD PHARMACEUTICALS, INC. (ARWR)
ahb-137POINT Biopharma Global Inc. (PNT)
ahb-171POINT Biopharma Global Inc. (PNT)
ALG-001075Aligos Therapeutics, Inc. (ALGS)
ALG-125755Aligos Therapeutics, Inc. (ALGS)
antihistamineARROWHEAD PHARMACEUTICALS, INC. (ARWR)
arc-520ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
ARC-521 InjectionARROWHEAD PHARMACEUTICALS, INC. (ARWR)
ARO-HBVARROWHEAD PHARMACEUTICALS, INC. (ARWR)
diphenhydramineARROWHEAD PHARMACEUTICALS, INC. (ARWR)
Duloxetine- AcetaminophenARROWHEAD PHARMACEUTICALS, INC. (ARWR)
EDP-514ENANTA PHARMACEUTICALS INC (ENTA)
IMC-I109VImmunocore Holdings plc (IMCR)
JNJ-56136379ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
nucleoside analoguePOINT Biopharma Global Inc. (PNT)
Nucleoside AnalogueArbutus Biopharma Corp (ABUS)
pbgene-hbvPRECISION BIOSCIENCES INC (DTIL)
pbgene-liverPRECISION BIOSCIENCES INC (DTIL)
peripheral ivCurative Biotechnology Inc (CUBT)
Pregabalin- AcetaminophenARROWHEAD PHARMACEUTICALS, INC. (ARWR)
tenofovirARROWHEAD PHARMACEUTICALS, INC. (ARWR)

Compare drugs

Nabi-HB vs xin ao xing oleanolic acidNabi-HB vs dtap-ipv-hep b-prp-t combined vaccineNabi-HB vs na therapy

Frequently asked questions

How many drugs are in development for Hepatitis B?

BioSniper tracks 71 drugs in development for Hepatitis B across 21 companies.

How many clinical trials target Hepatitis B?

There are 12 clinical trials targeting Hepatitis B tracked by BioSniper.

What is the prevalence of Hepatitis B?

The estimated prevalence of Hepatitis B is approximately 900.0 per 100,000 population.

Deep-dive into Hepatitis B

Full trial data, competitive analysis, and AI-powered pipeline tracking.

Start Free Analysis
    Hepatitis B — Drugs in Development & Clinical Trials | BioSniper